Kymriah’s 33.5 Million Yen Price Tag Favorably Received by JMA

May 16, 2019
Yoshitake Yokokura, president of the Japan Medical Association (JMA), on May 15 favorably received the 33.5 million yen NHI price given to Novartis Pharma’s CAR-T cell therapy Kymriah (tisagenlecleucel), saying it is about two-thirds of its US price. Speaking to...read more